HRTX Profile
Heron Therapeutics, Inc., a pioneering biotechnology firm headquartered in San Diego, California, specializes in developing innovative treatments aimed at addressing critical unmet needs in patient care. Central to its portfolio are proprietary product candidates harnessing Biochronomer, an advanced drug delivery technology. This platform enables sustained release of a variety of short-acting pharmacological agents over periods ranging from days to weeks following a single administration.
Among its notable offerings, Heron Therapeutics markets SUSTOL (granisetron), an extended-release injection designed to prevent acute and delayed nausea and vomiting linked with moderately emetogenic chemotherapy. Additionally, the company provides CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist, tailored for the prevention of nausea and vomiting induced by highly emetogenic cancer chemotherapy, as well as moderate regimens.
Heron Therapeutics continues to advance its pipeline with ZYNRELEF, a dual-acting local anesthetic combining bupivacaine and a low-dose anti-inflammatory drug, meloxicam. This candidate targets effective pain management post-surgery. Further bolstering its innovation efforts, the company is actively developing HTX-019 for postoperative nausea and vomiting prevention, alongside HTX-034, currently in Phase Ib/II clinical studies for managing postoperative pain in patients undergoing bunionectomy.
Founded in 1983 as A.P. Pharma, Inc., and rebranded as Heron Therapeutics, Inc. in January 2014, the company has forged a reputation for groundbreaking research and development in biopharmaceuticals. Heron Therapeutics remains dedicated to advancing therapeutic options through cutting-edge technology and a commitment to improving patient outcomes worldwide.
|
